Amylyx’s ALS drug launch starts strong. That could be trouble for the FDA
Behind the stellar launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug make it more complicated to pull it from the market if we find out next year that it doesn’t work?